Letter to the Editor regarding the review of literature about aplastic anaemia complicating systemic lupus rythematosusCorrespondence Address :
Dr. Amin Saburi,
Chemical Injuries Research Center,
Baqiyatallah university of medical sciences,
Mollasadra St, Vanak Sq, Tehran, IR. Iran.
Tel/Fax: +98-2188600067, E-mail: firstname.lastname@example.org
We read with interest, Dr. Wesley Jose et al.âs paper, ââAplastic anaemia complicating systemic lupus erythematosus (SLE) at a presentation: a clinical vignette and review of literatureâ, Journal of Clinical and Diagnostic Research 2011 June, 5(3): 637-639 (1). They skillfully reported an interesting case of Systemic Lupus Erythematosus (SLE) who initially presented with pancytopaenia, with the diagnosis of secondary Aplastic Anaemia (AA) and also she had responded to high dose Dexamethasone for four days, dramatically. Also, they asserted that they had reviewed the literature and had found only 16 reports for a total number of 19 patients. But, it seems that their review was not proper and that they had missed some reports. We reviewed the English literature exactly and found 6 reports which were missed until Jan 2011 (when Wesley et al.âs manuscript was submitted) (2),(3),(4),(5),(6),(7).
Various treatment protocols were used for these patients, but it seemed that some of these patients hadnât responded to the treatment well. In the six previous studies that had been ignored, anti-thymocyte globulin (ATG), granulocyte colony-stimulating factors (G-CSF) and cyclosporine had been used and they had been relatively effective. They revealed that a short course of high dose Dexamethasone was effective for acquire AA which was secondary to SLE. Plasmapheresis, cyclophosphamide, oxymethalone, prednisolone, methylprednisolone, androgens, plaquenil and antithymocyte globulin also had been used to treat these patients, but it appeared that this was the first time that Dexamethasone was successfully used for the treatment.
Recently, new biologic medications such as Rituximab (a CD20 positive B cell lymphocyte suppressor) were recommended for the lupus patients who were complicated with severe and refractory haematologic disorders (8). Regarding the aetiological mechanism of AA which is secondary to SLE (dysregulation of the T and B lymphocyte cells or the auto-antibodies that results in the destruction of the multi potential bone marrow stem cells), it is expected that the role of new biologic drugs will be bolder in these patients. Finally, the cases with SLE and acquired AA can benefit by a new biologic treatment. However, at the first step, the use of classic immunosuppressive drugs is safer and cheaper. Sincerely,
Financial OR OTHER COMPETING INTERESTS:
Date of Submission: Nov 11, 2011
Date of Peer Review: Feb 05, 2012
Date of Acceptance: Mar 14, 2012
Date of Publishing: Apr 20, 2012
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)